Medicare announced Thursday that it will limit its coverage of the pricey new drug Aduhelm to Alzheimer’s patients enrolled in clinical trials of the drug.
Medicare announced Thursday that it will limit its coverage of the pricey new drug Aduhelm to Alzheimer’s patients enrolled in clinical trials of the drug.